|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000196975 |
Summary for ANXA4 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000196975 | Gene symbol | ANXA4 |
| Gene name | annexin A4 | |
| HGNC | 542 | |
| Entrez ID | 307 | |
| Gene type | protein_coding | |
| Synonyms | ANXA4| | |
| UniProtAcc | P09525 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000196975 | ANXA4 | DB00591 | Fluocinolone acetonide | SmallMoleculeDrug |
| ENSG00000196975 | ANXA4 | DB09130 | Copper | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for ANXA4 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| ANXA4 | 2.45e+04 | 1.54e+00 | 3.45e-01 | 4.47e+00 | 7.81e-06 | 4.52e-05 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for ANXA4 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for ANXA4 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for ANXA4 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for ANXA4 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | ANXA4-009 | chr2_69758475_+ | 2.97e-01 | 6.53e-01 | -2.49e+00 | 1.27e-02 | 4.26e-02 | -3.56e-01 |
| KIRC | ANXA4-009 | chr2_69808718_+ | 2.13e-01 | 2.65e-01 | -1.99e+00 | 4.69e-02 | 4.96e-02 | -5.24e-02 |
| KIRC | ANXA4-009 | chr2_69809620_+ | 3.77e-01 | 3.19e-01 | 2.19e+00 | 2.85e-02 | 4.61e-02 | 5.80e-02 |
| KIRC | ANXA4-009 | chr2_69809716_+ | 2.30e-01 | 1.64e-01 | 2.60e+00 | 9.21e-03 | 4.20e-02 | 6.61e-02 |
| COAD | ANXA4-009 | chr2_69744222_+ | 1.31e-01 | 4.43e-01 | -2.19e+00 | 2.85e-02 | 3.85e-02 | -3.11e-01 |
| COAD | ANXA4-009 | chr2_69758162_+ | 4.02e-01 | 2.35e-01 | 3.46e+00 | 5.32e-04 | 1.36e-02 | 1.67e-01 |
| COAD | ANXA4-009 | chr2_69758438_+ | 6.09e-01 | 7.48e-01 | -1.98e+00 | 4.79e-02 | 4.90e-02 | -1.38e-01 |
| COAD | ANXA4-009 | chr2_69758475_+ | 2.93e-01 | 5.56e-01 | -3.58e+00 | 3.49e-04 | 1.36e-02 | -2.63e-01 |
| COAD | ANXA4-009 | chr2_69759090_+ | 3.41e-01 | 1.93e-01 | 2.06e+00 | 3.90e-02 | 4.48e-02 | 1.48e-01 |
| STAD | ANXA4-009 | chr2_69746105_+ | 3.06e-01 | 1.56e-01 | 2.49e+00 | 1.29e-02 | 4.96e-02 | 1.50e-01 |
| STAD | ANXA4-009 | chr2_69746901_+ | 2.36e-01 | 2.74e-01 | -2.02e+00 | 4.36e-02 | 4.96e-02 | -3.85e-02 |
| STAD | ANXA4-009 | chr2_69750444_+ | 4.63e-01 | 3.59e-01 | 2.10e+00 | 3.58e-02 | 4.96e-02 | 1.04e-01 |
| STAD | ANXA4-009 | chr2_69750554_+ | 3.37e-01 | 2.21e-01 | 2.24e+00 | 2.51e-02 | 4.96e-02 | 1.16e-01 |
| STAD | ANXA4-009 | chr2_69751248_+ | 1.57e-01 | 2.50e-01 | -2.80e+00 | 5.12e-03 | 4.96e-02 | -9.26e-02 |
| STAD | ANXA4-009 | chr2_69757068_+ | 2.70e-01 | 3.24e-01 | -2.07e+00 | 3.85e-02 | 4.96e-02 | -5.41e-02 |
| STAD | ANXA4-009 | chr2_69757812_+ | 2.74e-01 | 1.53e-01 | 2.57e+00 | 1.01e-02 | 4.96e-02 | 1.21e-01 |
| STAD | ANXA4-009 | chr2_69758275_+ | 3.39e-01 | 2.44e-01 | 2.64e+00 | 8.34e-03 | 4.96e-02 | 9.48e-02 |
| STAD | ANXA4-009 | chr2_69758475_+ | 5.48e-01 | 4.47e-01 | 2.22e+00 | 2.62e-02 | 4.96e-02 | 1.01e-01 |
| STAD | ANXA4-009 | chr2_69758491_+ | 4.52e-01 | 3.75e-01 | 2.36e+00 | 1.85e-02 | 4.96e-02 | 7.63e-02 |
| STAD | ANXA4-009 | chr2_69758947_+ | 2.55e-01 | 2.96e-01 | -2.06e+00 | 3.94e-02 | 4.96e-02 | -4.06e-02 |
| STAD | ANXA4-009 | chr2_69809713_+ | 2.95e-01 | 2.46e-01 | 2.27e+00 | 2.33e-02 | 4.96e-02 | 4.88e-02 |
| STAD | ANXA4-009 | chr2_69810144_+ | 2.50e-01 | 3.44e-01 | -2.00e+00 | 4.51e-02 | 4.96e-02 | -9.42e-02 |
| PAAD | ANXA4-003 | chr2_69822179_+ | 4.91e-01 | 3.02e-01 | 2.24e+00 | 2.52e-02 | 4.66e-02 | 1.89e-01 |
| ESCA | ANXA4-009 | chr2_69769802_+ | 1.75e-01 | 1.23e-01 | 2.20e+00 | 2.75e-02 | 4.99e-02 | 5.21e-02 |
| ESCA | ANXA4-003 | chr2_69822179_+ | 3.68e-01 | 4.88e-01 | -1.96e+00 | 5.00e-02 | 5.00e-02 | -1.20e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for ANXA4 |
| TFs related to ANXA4. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | ZNF235 | ANXA4 | 4.33e+00 | 9.90e-01 | 2.06e+00 | 4.17e-04 | Male-biased |
| BRCA | ZNF287 | ANXA4 | 4.13e+00 | 9.85e-01 | 2.07e+00 | 8.11e-04 | Male-biased |
| BRCA | ZNF487 | ANXA4 | 4.06e+00 | 9.84e-01 | 2.00e+00 | 8.15e-04 | Male-biased |
| MESO | ZNF418 | ANXA4 | 2.09e+00 | 6.67e-04 | 4.10e+00 | 9.87e-01 | Female-biased |
| READ | ZNF418 | ANXA4 | 2.98e+00 | 3.29e-04 | 4.78e+00 | 9.95e-01 | Female-biased |
| READ | ZNF879 | ANXA4 | 2.96e+00 | 2.15e-03 | 4.19e+00 | 9.85e-01 | Female-biased |
| ANXA4 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for ANXA4 |
| RBPs related to ES in ANXA4. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| READ | RBM5 | exon_skip_326239 | 7.31e+00 | 9.83e-01 | 6.93e+00 | 5.55e-03 | Male-biased |
| LGG | HNRNPH2 | exon_skip_326229 | 6.49e+00 | 9.81e-01 | 5.98e+00 | 1.59e-03 | Male-biased |
| PAAD | SRSF2 | exon_skip_326234 | 7.16e+00 | 9.38e-03 | 7.47e+00 | 9.80e-01 | Female-biased |
| HNSC | HNRNPH2 | exon_skip_326229 | 6.01e+00 | 6.18e-04 | 6.62e+00 | 9.83e-01 | Female-biased |
| ANXA4 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs75186773 | chr2:61302890:T:C | - | 0.16055460210992 | 0.029867194679228 | LIHC | Female-baised eQTL |
| rs140496018 | chr2:76798162:G:A | - | 0.160104364564637 | 0.0367489730039095 | LIHC | Female-baised eQTL |
| rs1186698 | chr2:61434960:G:A | - | 0.12432911958405 | 0.0379398421157501 | LIHC | Female-baised eQTL |
| rs2971851 | chr2:66175373:A:G | - | -0.102902430114836 | 0.0165306349014434 | KIRC | Female-baised eQTL |
| rs1465084 | chr2:78018826:T:C | - | 0.0910170279601688 | 0.0301780025251682 | KIRC | Female-baised eQTL |
| rs7584210 | chr2:77993222:C:A | - | 0.0912697564506675 | 0.0304590541150679 | KIRC | Female-baised eQTL |
| rs1918253 | chr2:78026726:A:G | - | 0.0896483236675817 | 0.0351610407372785 | KIRC | Female-baised eQTL |
| rs7585320 | chr2:77980988:A:G | - | 0.0926486210834829 | 0.0397180424950893 | KIRC | Female-baised eQTL |
| rs6705965 | chr2:77976968:T:C | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs1819001 | chr2:77978872:C:A | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs1609074 | chr2:77979349:T:C | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs1609073 | chr2:77979728:C:T | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs1115236 | chr2:77984875:A:G | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs7562561 | chr2:77987781:G:A | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs4852445 | chr2:77990188:G:A | - | 0.088063647949194 | 0.0459427455444676 | KIRC | Female-baised eQTL |
| rs1527181 | chr2:77976105:T:C | - | 0.0875339262580792 | 0.049617898625144 | KIRC | Female-baised eQTL |
| rs1852474 | chr2:77978808:T:A | - | 0.0875339262580792 | 0.049617898625144 | KIRC | Female-baised eQTL |
| rs10195694 | chr2:77983130:T:G | - | 0.0875339262580792 | 0.049617898625144 | KIRC | Female-baised eQTL |
| rs12468450 | chr2:61769146:G:C | - | 0.0507277945333948 | 0.0108299273590843 | LUAD | Female-baised eQTL |
| rs12474106 | chr2:63515903:C:T | - | 0.0488704916432266 | 0.0231982096361997 | LUAD | Female-baised eQTL |
| rs80001725 | chr2:63149961:A:T | - | 0.0482673374886198 | 0.0293610429985532 | LUAD | Female-baised eQTL |
| rs79559226 | chr2:63236983:G:A | - | 0.0481166623103464 | 0.030429779009711 | LUAD | Female-baised eQTL |
| rs76605442 | chr2:62594904:G:A | - | 0.052581807559499 | 0.0314898335402908 | LUAD | Female-baised eQTL |
| rs6705417 | chr2:74743810:G:A | - | 0.0396851009885122 | 0.0361822701265187 | LUAD | Female-baised eQTL |
| rs6740218 | chr2:61631954:T:C | - | -0.0307467660147262 | 0.0491046090085552 | LUAD | Female-baised eQTL |
| rs59923167 | chr2:71440604:G:A | - | 0.114308233688962 | 0.0453381240197739 | COAD | Female-baised eQTL |
| rs57092473 | chr2:71440419:A:G | - | 0.113683860978671 | 0.0478220685904544 | COAD | Female-baised eQTL |
| rs10168204 | chr2:71444476:A:G | - | 0.113683860978671 | 0.0478220685904544 | COAD | Female-baised eQTL |
| rs13034890 | chr2:71203412:T:C | - | 0.0816807617172346 | 0.0491265986018365 | COAD | Female-baised eQTL |
| rs12615297 | chr2:71204755:G:A | - | 0.0816807617172346 | 0.0491265986018365 | COAD | Female-baised eQTL |
| rs13006773 | chr2:71178248:G:A | - | 0.0942548436724356 | 0.0493996791475468 | COAD | Female-baised eQTL |
| rs10188295 | chr2:71418874:G:A | - | 0.113185185033127 | 0.0497656033466108 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12993095 | chr2:67038447:T:C | - | 0.162635648283939 | 0.0418617411862844 | SARC | Male-baised eQTL |
| rs581955 | chr2:67463091:G:A | - | 0.0590406614534272 | 0.0395597837840778 | KIRC | Male-baised eQTL |
| rs55830965 | chr2:66670779:T:G | - | 0.0717408933771578 | 0.0192788703023771 | BLCA | Male-baised eQTL |
| rs191401130 | chr2:66632541:C:A | - | 0.070882557941643 | 0.0226522787037965 | BLCA | Male-baised eQTL |
| rs142083074 | chr2:66632912:G:C | - | 0.070882557941643 | 0.0226522787037965 | BLCA | Male-baised eQTL |
| rs56130904 | chr2:66634477:C:T | - | 0.070882557941643 | 0.0226522787037965 | BLCA | Male-baised eQTL |
| rs17032335 | chr2:66636755:T:C | - | 0.070882557941643 | 0.0226522787037965 | BLCA | Male-baised eQTL |
| rs116704653 | chr2:66621583:G:T | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs114128092 | chr2:66621584:G:A | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs4505509 | chr2:66623433:T:G | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs192506056 | chr2:66623818:T:G | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs56311538 | chr2:66626489:C:T | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs139535049 | chr2:66629828:C:G | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs183081364 | chr2:66632564:C:T | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs151230964 | chr2:66632812:G:A | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs56211113 | chr2:66634619:A:G | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs72808818 | chr2:66635654:A:G | - | 0.085190742721633 | 0.0233812632794549 | BLCA | Male-baised eQTL |
| rs67054138 | chr2:66639914:T:C | - | 0.0700629763442876 | 0.0236451165390975 | BLCA | Male-baised eQTL |
| rs116816984 | chr2:66640218:C:T | - | 0.0700629763442876 | 0.0236451165390975 | BLCA | Male-baised eQTL |
| rs113141186 | chr2:66637212:A:G | - | 0.0843179703911522 | 0.0243425927532464 | BLCA | Male-baised eQTL |
| rs143063084 | chr2:66647341:C:T | - | 0.0697808725811084 | 0.0246562222695591 | BLCA | Male-baised eQTL |
| rs140249857 | chr2:66648447:C:T | - | 0.0697808725811084 | 0.0246562222695591 | BLCA | Male-baised eQTL |
| rs79707217 | chr2:66648735:T:C | - | 0.0697808725811084 | 0.0246562222695591 | BLCA | Male-baised eQTL |
| rs17032337 | chr2:66638558:G:T | - | 0.0697638454143147 | 0.0250051785617357 | BLCA | Male-baised eQTL |
| rs9941639 | chr2:66669586:G:T | - | 0.0694216005730597 | 0.0269046735597003 | BLCA | Male-baised eQTL |
| rs9941653 | chr2:66670124:C:T | - | 0.0694216005730597 | 0.0269046735597003 | BLCA | Male-baised eQTL |
| rs113982455 | chr2:66637651:G:C | - | 0.082835702302051 | 0.0276080208496773 | BLCA | Male-baised eQTL |
| rs67294009 | chr2:66638485:C:T | - | 0.082835702302051 | 0.0276080208496773 | BLCA | Male-baised eQTL |
| rs55805041 | chr2:66651990:A:T | - | 0.0693331909917417 | 0.027723471527624 | BLCA | Male-baised eQTL |
| rs68044562 | chr2:66652695:G:A | - | 0.0693331909917417 | 0.027723471527624 | BLCA | Male-baised eQTL |
| rs67981426 | chr2:66655144:A:G | - | 0.0693331909917417 | 0.027723471527624 | BLCA | Male-baised eQTL |
| rs66923107 | chr2:66655958:G:A | - | 0.0693331909917417 | 0.027723471527624 | BLCA | Male-baised eQTL |
| rs68170325 | chr2:66652734:C:T | - | 0.0825717464209434 | 0.02852372175565 | BLCA | Male-baised eQTL |
| rs67710556 | chr2:66654338:A:C | - | 0.0825717464209434 | 0.02852372175565 | BLCA | Male-baised eQTL |
| rs60931071 | chr2:66656028:T:C | - | 0.0825717464209434 | 0.02852372175565 | BLCA | Male-baised eQTL |
| rs66533267 | chr2:66663710:G:C | - | 0.0825717464209434 | 0.02852372175565 | BLCA | Male-baised eQTL |
| rs181523914 | chr2:66620711:G:A | - | 0.0825787790191417 | 0.0310026207749049 | BLCA | Male-baised eQTL |
| rs60395529 | chr2:66612660:C:G | - | 0.0790342301336546 | 0.0372708087717457 | BLCA | Male-baised eQTL |
| rs6714984 | chr2:71406287:C:T | - | 0.097289806536138 | 0.0476517435876657 | LUAD | Male-baised eQTL |
| rs12105679 | chr2:78726812:G:C | - | -0.0518748199470686 | 0.0224299021487447 | COAD | Male-baised eQTL |
| rs11695335 | chr2:78739814:C:T | - | -0.0522804768452189 | 0.0280895426472843 | COAD | Male-baised eQTL |
| rs12612925 | chr2:69885448:G:A | - | 0.0505163407714759 | 0.031619927242821 | COAD | Male-baised eQTL |
| rs72919716 | chr2:78670141:A:G | - | -0.0508495983590068 | 0.0330953493156901 | COAD | Male-baised eQTL |
| rs17015555 | chr2:78695746:C:T | - | -0.0516122889995637 | 0.0333297078157299 | COAD | Male-baised eQTL |
| rs59504369 | chr2:78720317:G:A | - | -0.0504623085336651 | 0.0334266731391499 | COAD | Male-baised eQTL |
| rs12105200 | chr2:78727348:C:A | - | -0.0504623085336651 | 0.0334266731391499 | COAD | Male-baised eQTL |
| rs112855131 | chr2:78720993:A:T | - | -0.0502977359457867 | 0.0358453216942231 | COAD | Male-baised eQTL |
| rs12620510 | chr2:78718179:A:G | - | -0.0504715395132931 | 0.037986250724836 | COAD | Male-baised eQTL |
| rs1452044 | chr2:78718629:A:G | - | -0.0504715395132931 | 0.037986250724836 | COAD | Male-baised eQTL |
| rs61607019 | chr2:78683219:T:C | - | -0.0509251385875981 | 0.0382219462753251 | COAD | Male-baised eQTL |
| rs112303758 | chr2:78689392:G:C | - | -0.0506365702534831 | 0.0385436994257497 | COAD | Male-baised eQTL |
| rs62152020 | chr2:69920532:C:T | - | 0.0491919385202469 | 0.039434739843364 | COAD | Male-baised eQTL |
| rs35344582 | chr2:69920961:C:T | - | 0.0491919385202469 | 0.039434739843364 | COAD | Male-baised eQTL |
| rs10496175 | chr2:69926716:T:C | - | 0.0491919385202469 | 0.039434739843364 | COAD | Male-baised eQTL |
| rs111443248 | chr2:78663633:T:C | - | -0.0499342503322544 | 0.0397514638710566 | COAD | Male-baised eQTL |
| rs11126679 | chr2:78661436:G:T | - | -0.0518401058128265 | 0.040205670544197 | COAD | Male-baised eQTL |
| rs17015611 | chr2:78766640:T:C | - | -0.0524592462855229 | 0.0438923976722966 | COAD | Male-baised eQTL |
| rs144756983 | chr2:78724940:C:G | - | -0.0512807719145287 | 0.0451042478233445 | COAD | Male-baised eQTL |
| rs2037451 | chr2:78643112:T:C | - | -0.0490438006057247 | 0.0452150780356991 | COAD | Male-baised eQTL |
| rs1879112 | chr2:78642735:G:C | - | -0.0496420920574429 | 0.0459581397328229 | COAD | Male-baised eQTL |
| rs6738783 | chr2:69893476:A:G | - | 0.0465985783498395 | 0.0463591041815475 | COAD | Male-baised eQTL |
| rs58794352 | chr2:78644322:G:A | - | -0.0499020850689272 | 0.0469882975530504 | COAD | Male-baised eQTL |
| rs72921840 | chr2:78732146:C:T | - | -0.0508385127329239 | 0.0470938069995014 | COAD | Male-baised eQTL |
| rs3755391 | chr2:69914387:C:T | - | 0.047838112348585 | 0.0477009697546638 | COAD | Male-baised eQTL |
| rs1048165 | chr2:69904832:A:C | - | 0.047598472963252 | 0.0492713991023657 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000196975 |
| CpG Site: cg25099065 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.396027759412108 | |
 | Gene ID: ENSG00000196975 |
| CpG Site: cg17719951 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.466107492029371 | |
 | Gene ID: ENSG00000196975 |
| CpG Site: cg06635952 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.10603905904591 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg25099065 | chr2:69767093 | gene | -0.396027759412108 | 3.36401754518587e-21 | -0.5128940841410792 | 9.572634553754681e-26 | THCA |
| cg17719951 | chr2:69743507 | gene | -0.466107492029371 | 9.06718613943113e-52 | -0.7865401315951326 | 6.939151282762684e-55 | LUAD |
| cg06635952 | chr2:69798737 | gene | -0.10603905904591 | 2.2881114084956e-05 | -0.3515319897323591 | 2.3323960801323947e-08 | LGG |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of ANXA4 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000196975 | ANXA4 | C0007097 | Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0023903 | Liver neoplasms | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0026998 | Acute Myeloid Leukemia, M1 | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0032927 | Precancerous Conditions | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0205699 | Carcinomatosis | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0282313 | Condition, Preneoplastic | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1257925 | Mammary Carcinoma, Animal | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C1879321 | Acute Myeloid Leukemia (AML-M2) | 1 | CTD_human |
| ENSG00000196975 | ANXA4 | C2239176 | Liver carcinoma | 1 | CTD_human |
